Navigation Links
Accera, Inc. to Present at the 4th Annual BIO Investor Forum
Date:10/4/2007

BROOMFIELD, Colo., Oct. 4 /PRNewswire/ -- Accera Inc., a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases, announced today that the company will be participating in the 4th Annual BIO Investor Forum next week at the Palace Hotel in San Francisco:

-- Dr. Lauren Costantini, Vice President of Clinical Development, will

contribute to the panel discussion, "Alzheimer's Disease - Novel

Mechanisms and Targets Renewing the Future of Patients" on Wednesday,

October 10 at 9:10 a.m. PDT.

-- Dr. Steve Orndorff, President and CEO, will present on Thursday,

October 11 at 11:00 a.m. PDT.

Dr. Orndorff will provide an overview of Accera and its technology platform as well as a summary of the positive data from the company's Phase IIb studies of its lead therapeutic product, Ketasyn(TM) (AC-1202) in Alzheimer's disease (AD) and age-associated memory impairment (AAMI). In both studies, Ketasyn was shown to significantly improve memory and cognition using a battery of neuropsychometric tests, including ADAS-Cog, the FDA's gold- standard efficacy measure for AD drugs. Ketasyn was also well tolerated in both indications, even when taken in addition to existing AD drugs, making it a promising candidate for a cotherapeutic approach to treating AD.

About Accera, Inc.

Based in Broomfield, CO, Accera, Inc. is a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, Ketasyn(TM) (AC-1202), is a first-in-class molecule that earlier this year completed successful Phase II clinical trials for Alzheimer's disease and age-associated memory impairment (AAMI). A key element of Accera's strategy is to develop AC-1202 and other proprietary small molecule compounds in its pipeline with corporate partners for a range of memory and cognition disorders associated with neurological conditions and aging. '/>"/>

SOURCE Accera Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 Virobay, Inc. today announced ... has reached an important milestone, as Virobay has now ... a selective cathepsin S inhibitor.   The ... randomized, placebo-controlled study designed to evaluate the safety, tolerability, ... healthy adults. "The initiation of this Phase ...
(Date:5/23/2013)... , May 23, 2013 Z Trim ... value-added ingredients to a variety of industries, announced that ... a panel discussion at this year,s National Restaurant Association ... 2013, on behalf of the Research Chefs Association.  Chef ... Restaurants: The Good, the Bad and the Ugly," joining ...
(Date:5/23/2013)... EASTON, Mass. , May 23, 2013 ... today announced that the Company will host a teleconference ... to provide a business update. The teleconference information is ... Time: 11:00 a.m. Eastern Daylight Time (EDT) ... ); (302) 607-2001 (Int,l) Passcode: VS22823 ...
(Date:5/23/2013)... BUSAN, South Korea , May 23, 2013 ... collaboration with SillaJen, Inc., a private biotherapeutics and ... of targeted biological products for cancer, announced today ... antibodies in patients treated with the oncolytic and ... This research was published in the ...
Breaking Biology Technology:Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... Partner with Biocareercenter.com ... Oct. 2 According to the National,Postdoc Association, more ... the United States today. With only 30 percent of,this ... emerging need to find more quality jobs in the ...
... Calhoun Credits Early Diagnosis with Saving his Life, ... 2007:,The MedTech Conference will highlight how everyday patients are ... as speakers on the,diversity and strength of the economic ... 1 through Oct. 3., Co-writing "A PASSION TO ...
... MISSISSAUGA, ON, Oct. 2 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: ... the research and,commercial development of technologies targeting the ... its,quarterly results after the close of the North ... conference call and audio web cast will also,be ...
Cached Biology Technology:Bio Career Center Launches First Online Jobs Board for Life Science PhDs, MDs 2U.S. Commerce Secretary Gutierrez to Address AdvaMed 2007 2U.S. Commerce Secretary Gutierrez to Address AdvaMed 2007 3Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 2Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 3Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 4
(Date:5/23/2013)... Public Health at Emory University, along with partners ... a $4 million grant over four years to ... and Exposome Research Center: Understanding Lifetime Exposures). The ... in the United States. , The HERCULES ... Environmental Health Sciences (NIEHS) of the National Institutes ...
(Date:5/23/2013)... cancer patients unnecessarily undergo surgery or harsh treatments ... slow-growing and aggressive forms of the disease. Researchers ... Medical Institutes are developing technology that allows patients ... relatively mild treatments or take drastic measures. , ... an associate professor of biomedical engineering at Case ...
(Date:5/23/2013)... of the world,s largest and fastest growing open-access ... Frontiers in Bioengineering and Biotechnology . ... Frontiers in Bioengineering and Biotechnology will ... emerging bioengineering and biotechnology research to be disseminated ... and Biotechnology will provide an open-science and ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
... the Americas avoid competing for the same lunch, or ... from a new study by a pair of researchers ... shows that it,s not just chance that,s at play, ... force in the evolution of many carnivores, influencing such ...
... 10, 2009)The use of common and readily available screening ... scoring systemssuch as the Framingham Risk Scorehas the potential ... who are not originally thought to be at high ... Society of Interventional Radiology,s 34th Annual Scientific Meeting. About ...
... but scientists have found a Yellowstone National Park alga ... algae called Cyanidioschyzon -- thrives in extremely ... around hot springs, said Tim McDermott, professor in the ... State University. Cyanidioschyzon could someday help ...
Cached Biology News:American carnivores evolved to avoid each other, new study suggests 2Simple test helps predict heart attack risk 2Simple test helps predict heart attack risk 3Montana State team finds Yellowstone alga that detoxifies arsenic 2Montana State team finds Yellowstone alga that detoxifies arsenic 3
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
Normal Bovine Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin lev...
...
Biology Products: